drugset
drugset / Trial / NCT04085224

6x3 Crossover, Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy Volunteers

NCT04085224 ↗

Phase 1 Completed 24 enrolled LG Chem
RandomizedCrossoverSingle-blindOther

Summary

A Randomized, Open Label, Single Subcutaneous Dose 6x3 Crossover Study to Investigate the Relative Bioavailability, Safety and Tolerability among Different Eutropin Formulations in Healthy Volunteers

Timeline

Start
2019-09-10
Primary completion
2020-01-02
Completion
2020-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.